Similarities exist in hormone receptors of breast, prostate, and thyroid tumors. HER2 oncogene expression is known to be present in breast and prostate tumors, but conflicting data have been published about its presence in thyroid tumors. This uncertainty prompted us to examine the incidence of HER2 overexpression in normal and malignant thyroid tissue. Normal and neoplastic thyroid tissue samples from 46 female and 9 male patients were assayed for HER2 expression by immunohistochemical assay. Of the 55 total samples, 36 were from neoplasms and 19 were from benign tissues. Significant HER2 overexpression was not found in any benign or malignant thyroid tissue. Two of 6 thyroid carcinomas from male patients showed 1+ reactivity for HER2 expression on immunohistochemistry assay, but remained negative on fluorescene in sito hybridization confirmatory testing. No significant expression of HER2 was noted in benign or malignant thyroid tissue. These results cast doubt on the value of HER2 as a prognostic factor or possible target for specific antitumor therapy for thyroid cancer.
Get full access to this article
View all access options for this article.
References
1.
GreenleeRT, Hill-HarmonM, MurrayT, . Cancer sta-tistics, 2001. CA Cancer J Clin2001;51: 15–36
2.
GrimmO.Thyroid cancer.Cancer2001;163: 143–56.
3.
MazzaferriEL.Long-term outcome of patients with differ-entiated thyroid carcinoma: Effect of therapy.Endocr Pract2000; 6:469–76.
4.
AACE/AAES medical/surgical guidelines for clinical practice: Management of thyroid carcinoma.American Association of Clinical Endocrinologists.American College of Endocrinology. Endocr Pract2001;7: 202–20.
5.
HungMC, LauYK.Basic science of HER-2/neu: A review.Semin Oncol1999, 26:51.
6.
CarrowayKL3rd, SweeneyC.Localization and modulation of ErbB receptor tyrosine kinases.Curr Opin Cell Biol2001; 13: 1225–30.
7.
NagyP, JeneiA, DamjanovichSM, . Complexity of signal transduction mediated by ErbB2: Clues to the potential of receptor-targeted cancer therapy. Pathol Oncol Res1999;5: 255–71.
8.
YuD, HungMC.Overexpression of ErbB2 in cancer and ErbB2-targeting strategies.Oncogene19:6115–21.
PaikS, HazanR, FisherER, . Pathologic findings from the Nations Surgical Adjuvant Breast and Bowel Project: Prog-nostic significance of erb-B2 protein overexpression in primary breast cancer. J Clin Oncol1990;8: 103–12.
11.
WinstanleyJ, CookeT, MurrayGD, . The long term prognostic significance of c-erb-B2 in primary breast cancer. Br J Cancer1991;63: 447–50.
12.
ToikkannenS, HelinH, IsolaJ, . Prognostic signifi-cance of Her-2 oncoprotein expression in breast cancer: A 30-year follow up. J Clin Oncol1992;12: 1965–91.
13.
CobleighM, VogelC, TripathyD, . Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc ASCO1998; 17: 98a.
14.
SlamonDJ, Leyland-JonesB, ShakS, . Use of chemo-therapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med2001;344: 783–92.
15.
YehS, LinHK, KangHY, . From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci U S A1999;96: 5458–63.
16.
CraftN, ShostakY, CareyM, . A mechanism for hor-mone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med1999;5: 280–5.
17.
MoroteJ, de TorresI, CaceresC, . Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastatic prostate cancer. Int J Cancer1999;84: 421–5.
18.
RossJS, SheehanCE, Hayner-BuchanAM, . Prognos-tic significance of HER-2/neu gene amplification status by fluo-rescence in situ hybridization of prostate carcinoma. Cancer1997; 79:2162–70.
19.
ClarkOH, GerendPL, DavisM, . Estrogen and thyroid stimulating hormone (TSH) receptors in neoplastic and non-neoplastic human thyroid tissue. J Surg Res1985;38: 89–96.
20.
HamplR, NemecJ, HeresovaJ, . Estrogen receptors in human goitrous and neoplastic thyroid. Endocrinol Exp1985; 19: 227–30.
21.
BonacciR, PincheraA, FierabracciP, . Relevance of estrogen and progesterone receptors enzyme immunoassay in ma-lignant, benign and surrounding normal thyroid tissue. Endocrinol Invest1996;19: 159–64.
22.
DalleValle L, RaminaA, VianelloS, . Potenital for estrogen synthesis and action in human normal and neoplastic thyroid tissues. J Clin Endocrinol Metab1998;83: 3702–9.
23.
ColomerA, Martinez-MasJV, Matias-GuiuX, . Sex steroid hormone receptors in human medullary thyroid carcinoma. Mod Pathol1996;9: 68–72.
24.
ZaccheroniV, VacircaA, LucciE, . An immunohisto-chemical study of progesterone receptor in thyroidal Hurthle cells tumors. J Exp Clin Cancer Res1998;17: 291–8.
25.
LemoineNR, WyllieFS, LillehaugJR, . Absence of abnormalities of the c-erbB-1 and c-erbB-2 proto-oncogenes in human thyroid neoplasia. Eur J Cancer1990;26: 777–9.
26.
AaslandR, LillehaugJR, MaleR, . Expression of on-cogenes in thyroid tumors: Coexpression of c-erbB2/nue and c-erbB. Br J Cancer1988;57: 358–63.
27.
HaugenDR, AkslenLA, VarhaugJE, . Expression of c-erbB-2 protein in papillary thyroid carcinomas. Br J Cancer1992;65: 832–7.
28.
UtrillaJC, Martin-LacaveI, San MartinMV, . Expression of c-erbB-2 oncoprotein in human thyroid tumors. Histopa-thology1999;34: 60–5.
29.
HaugenDR, AkslenLA, VarhaugJE, . Demonstration of a TGF-alpha-EGF-receptor autocrine loop and c-myc protein-overexpression in papillary thyroid carcinomas. Int J Cancer1993; 55:37–43.
30.
HaugenDR, AkslenLA.VarhaugJE, . Expression of c-erbB-3 and c-erbB-4 proteins in papillary thyroid carcinomas. Cancer Res1996;56: 1184–8.
31.
AkslenLA, VarhaugJE.Oncoproteins and tumor progression in papillary thyroid carcinoma: Presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival.Cancer1995;76: 1643–54.
32.
KlapperLN, KirschbaumMH, SelaM, . Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res2000;77: 25–79.
33.
SeidmanAD, FourneirMN, EstevaFJ, . Weekly trastu-zumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 jmmunophenotype and gene amplification. J Clin Oncol2001;19: 2587–95.
